636 related articles for article (PubMed ID: 2159373)
21. Role of bcl-2 in Epstein-Barr virus-induced malignant conversion of Burkitt's lymphoma cell line Akata.
Komano J; Takada K
J Virol; 2001 Feb; 75(3):1561-4. PubMed ID: 11152530
[TBL] [Abstract][Full Text] [Related]
22. Indole-3-carbinol induces cMYC and IAP-family downmodulation and promotes apoptosis of Epstein-Barr virus (EBV)-positive but not of EBV-negative Burkitt's lymphoma cell lines.
Perez-Chacon G; de Los Rios C; Zapata JM
Pharmacol Res; 2014 Nov; 89():46-56. PubMed ID: 25180456
[TBL] [Abstract][Full Text] [Related]
23. The intron enhancer of the immunoglobulin kappa gene activates c-myc but does not induce the Burkitt-specific promoter shift.
Polack A; Strobl L; Feederle R; Schweizer M; Koch E; Eick D; Wiegand H; Bornkamm GW
Oncogene; 1991 Nov; 6(11):2033-40. PubMed ID: 1945409
[TBL] [Abstract][Full Text] [Related]
24. Forward and reverse changes in Ig/myc translocation carrying tumors.
Klein G
Princess Takamatsu Symp; 1989; 20():135-42. PubMed ID: 2562178
[TBL] [Abstract][Full Text] [Related]
25. Reversion of tumorigenicity in an EBV-converted Burkitt's lymphoma line.
Klein G
Ciba Found Symp; 1989; 142():36-48; discussion 48-53. PubMed ID: 2545422
[TBL] [Abstract][Full Text] [Related]
26. Regulation of c-fgr proto-oncogene expression in Burkitt's lymphoma cells: effect of interferon treatment and relationship to EBV status and c-myc mRNA levels.
Sharp NA; Luscombe MJ; Clemens MJ
Oncogene; 1989 Aug; 4(8):1043-6. PubMed ID: 2548145
[TBL] [Abstract][Full Text] [Related]
27. Epstein-Barr virus-encoded poly(A)(-) RNA supports Burkitt's lymphoma growth through interleukin-10 induction.
Kitagawa N; Goto M; Kurozumi K; Maruo S; Fukayama M; Naoe T; Yasukawa M; Hino K; Suzuki T; Todo S; Takada K
EMBO J; 2000 Dec; 19(24):6742-50. PubMed ID: 11118209
[TBL] [Abstract][Full Text] [Related]
28. Deregulation of the proto-oncogene c-myc through t(8;22) translocation in Burkitt's lymphoma.
Gerbitz A; Mautner J; Geltinger C; Hörtnagel K; Christoph B; Asenbauer H; Klobeck G; Polack A; Bornkamm GW
Oncogene; 1999 Mar; 18(9):1745-53. PubMed ID: 10208435
[TBL] [Abstract][Full Text] [Related]
29. Hybridization of a myeloid leukemia-derived human cell line (K562) with a human Burkitt's lymphoma line (P3HR-1).
Klein G; Zeuthen J; Eriksson I; Terasaki P; Bernoco M; Rosén A; Masucci G; Povey S; Ber R
J Natl Cancer Inst; 1980 Apr; 64(4):725-38. PubMed ID: 6245297
[TBL] [Abstract][Full Text] [Related]
30. Characterization and comparison of two newly established Epstein-Barr virus (EBV)-negative and EBV-positive Burkitt's lymphoma cell lines. EBV-negative cell line with a low level of expression of ICAM-1 molecule and EBV-positive cell line with a high level of expression of ICAM-1 molecule.
Abe M; Tasaki K; Tominaga K; Fukuhara S; Imai S; Osato T; Wakasa H
Cancer; 1992 Feb; 69(3):763-71. PubMed ID: 1309680
[TBL] [Abstract][Full Text] [Related]
31. Establishment and comprehensive analysis of a new human transformed follicular lymphoma B cell line, Tat-1.
Denyssevych T; Lestou VS; Knesevich S; Robichaud M; Salski C; Tan R; Gascoyne RD; Horsman DE; Mayer LD
Leukemia; 2002 Feb; 16(2):276-83. PubMed ID: 11840295
[TBL] [Abstract][Full Text] [Related]
32. Cell phenotype dependent expression of MHC class I antigens in Burkitt's lymphoma cell lines.
Masucci MG; Klein E
Semin Cancer Biol; 1991 Feb; 2(1):63-71. PubMed ID: 1655115
[TBL] [Abstract][Full Text] [Related]
33. Epstein-Barr virus and its role in the pathogenesis of Burkitt's lymphoma: an unresolved issue.
Bornkamm GW
Semin Cancer Biol; 2009 Dec; 19(6):351-65. PubMed ID: 19619654
[TBL] [Abstract][Full Text] [Related]
34. Cationic lipids reduce time and dose of c-myc antisense oligodeoxynucleotides required to specifically inhibit Burkitt's lymphoma cell growth.
Williams SA; Chang L; Buzby JS; Suen Y; Cairo MS
Leukemia; 1996 Dec; 10(12):1980-9. PubMed ID: 8946941
[TBL] [Abstract][Full Text] [Related]
35. Retinoic acid induces changes in c-fgr proto-oncogene mRNA levels in Burkitt's lymphoma cells.
Faulkner L; Katz DR; Brickell PM
Immunobiology; 1993 Aug; 188(4-5):460-8. PubMed ID: 8244449
[TBL] [Abstract][Full Text] [Related]
36. Establishment of the novel B acute lymphoblastic leukemia (FAB L3) cell line KHM-10B with a 13q34 abnormality and constitutive expression of c-myc and max during cell cycle.
Sonoki T; Matsuzaki H; Miyamoto K; Taniwaki M; Yoshino T; Hata H; Yoshida M; Matsuno F; Nagasaki A; Kuribayashi N
Leukemia; 1995 Dec; 9(12):2093-9. PubMed ID: 8609722
[TBL] [Abstract][Full Text] [Related]
37. Characterization of EBV-positive lymphoblastoid cell lines obtained from HIV seropositive patients with or without lymphomas.
Roncella S; Di Celle PF; Cutrona G; Carbone A; Sessarego M; Dodi F; Foa R; Rowe M; Ferrarini M
Leukemia; 1992; 6 Suppl 3():12S-14S. PubMed ID: 1318463
[TBL] [Abstract][Full Text] [Related]
38. Cytogenetic study of a European Burkitt's lymphoma cell line.
Berger R; Bernheim A; Fellous M; Brouet JC
J Natl Cancer Inst; 1979 May; 62(5):1187-92. PubMed ID: 286095
[TBL] [Abstract][Full Text] [Related]
39. Expression of tumor-associated epitopes on Epstein-Barr virus-immortalized B-cells and Burkitt's lymphomas transfected with epithelial mucin complementary DNA.
Jerome KR; Bu D; Finn OJ
Cancer Res; 1992 Nov; 52(21):5985-90. PubMed ID: 1382849
[TBL] [Abstract][Full Text] [Related]
40. Integration of Epstein Barr virus near the breakpoint of a translocation 11;19 in a Burkitt's lymphoma cell line.
Wolf J; Pawlita M; Jox A; Kohls S; Bartnitzke S; Diehl V; Bullerdiek J
Cancer Genet Cytogenet; 1993 Jun; 67(2):90-4. PubMed ID: 8392436
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
